JP2015529655A5 - - Google Patents

Download PDF

Info

Publication number
JP2015529655A5
JP2015529655A5 JP2015525554A JP2015525554A JP2015529655A5 JP 2015529655 A5 JP2015529655 A5 JP 2015529655A5 JP 2015525554 A JP2015525554 A JP 2015525554A JP 2015525554 A JP2015525554 A JP 2015525554A JP 2015529655 A5 JP2015529655 A5 JP 2015529655A5
Authority
JP
Japan
Prior art keywords
registered trademark
statin
simvastatin
subject
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015525554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529655A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/053007 external-priority patent/WO2014022551A1/en
Publication of JP2015529655A publication Critical patent/JP2015529655A/ja
Publication of JP2015529655A5 publication Critical patent/JP2015529655A5/ja
Pending legal-status Critical Current

Links

JP2015525554A 2012-08-02 2013-07-31 アテローム性硬化症の処置方法 Pending JP2015529655A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261678992P 2012-08-02 2012-08-02
US61/678,992 2012-08-02
US201261695850P 2012-08-31 2012-08-31
US201261695807P 2012-08-31 2012-08-31
US61/695,850 2012-08-31
US61/695,807 2012-08-31
PCT/US2013/053007 WO2014022551A1 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017195835A Division JP2018012726A (ja) 2012-08-02 2017-10-06 アテローム性硬化症の処置方法

Publications (2)

Publication Number Publication Date
JP2015529655A JP2015529655A (ja) 2015-10-08
JP2015529655A5 true JP2015529655A5 (cg-RX-API-DMAC7.html) 2016-09-15

Family

ID=50028503

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015525554A Pending JP2015529655A (ja) 2012-08-02 2013-07-31 アテローム性硬化症の処置方法
JP2015525555A Pending JP2015524439A (ja) 2012-08-02 2013-07-31 アテローム性硬化症の処置方法
JP2017194137A Pending JP2018016637A (ja) 2012-08-02 2017-10-04 アテローム性硬化症の処置方法
JP2017195835A Pending JP2018012726A (ja) 2012-08-02 2017-10-06 アテローム性硬化症の処置方法
JP2019042213A Pending JP2019108389A (ja) 2012-08-02 2019-03-08 アテローム性硬化症の処置方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015525555A Pending JP2015524439A (ja) 2012-08-02 2013-07-31 アテローム性硬化症の処置方法
JP2017194137A Pending JP2018016637A (ja) 2012-08-02 2017-10-04 アテローム性硬化症の処置方法
JP2017195835A Pending JP2018012726A (ja) 2012-08-02 2017-10-06 アテローム性硬化症の処置方法
JP2019042213A Pending JP2019108389A (ja) 2012-08-02 2019-03-08 アテローム性硬化症の処置方法

Country Status (8)

Country Link
US (5) US10188693B2 (cg-RX-API-DMAC7.html)
EP (6) EP3662921A1 (cg-RX-API-DMAC7.html)
JP (5) JP2015529655A (cg-RX-API-DMAC7.html)
CN (3) CN110090304A (cg-RX-API-DMAC7.html)
AU (4) AU2013296494B2 (cg-RX-API-DMAC7.html)
CA (2) CA2880643A1 (cg-RX-API-DMAC7.html)
HK (2) HK1210962A1 (cg-RX-API-DMAC7.html)
WO (2) WO2014022551A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312066A (zh) * 2011-12-09 2017-11-03 康德生物医疗技术公司 芳香族阳离子肽及其用途
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
JP2015529655A (ja) * 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
CN110193077A (zh) * 2012-10-22 2019-09-03 康德生物医疗技术公司 降低与心脏衰竭相关的风险和与其相关的因素的方法
WO2015183970A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including flavonoid and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2015183985A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including naphthoquinones and uses thereof
RU2623876C2 (ru) * 2014-11-10 2017-06-29 Александр Владимирович Диковский Фармацевтическая композиция для лечения гиперлипидемии
WO2016190852A1 (en) * 2015-05-26 2016-12-01 Stealth Peptides International, Inc. Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
US20180318381A1 (en) * 2015-10-23 2018-11-08 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Methods of Treatment of Rhabdomyolysis
US11355245B2 (en) * 2016-05-03 2022-06-07 International Business Machines Corporation Identifying and ranking risk factors using trained predictive models
ES2871783T3 (es) * 2016-09-20 2021-11-02 Univ Aarhus Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
IL322723A (en) 2017-04-05 2025-10-01 Stealth Biotherapeutics Inc Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
GB202005439D0 (en) 2020-04-14 2020-05-27 Aurigen Medical Ltd A device for occlusion of a left a trial appendage of a heart

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
CA2455336A1 (en) 2001-08-10 2003-02-20 Novartis Ag Peptides that bind to atherosclerotic lesions
PT1599216E (pt) * 2003-02-04 2013-12-17 Cornell Res Foundation Inc Métodos de prevenção da transição de permeabilidade mitocondrial
DK2604285T3 (en) * 2003-05-01 2014-12-01 Cornell Res Foundation Inc Method and carrier complex for delivering molecules to cells
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
JP2009525281A (ja) * 2006-01-30 2009-07-09 イスラエル ベン デビッド ブライソン、 心臓血管系疾患、脳血管系疾患および他の血管系疾患の患者を治療するための組成物ならびに方法
JP4881385B2 (ja) 2006-08-30 2012-02-22 国立大学法人九州大学 スタチン封入ナノ粒子含有医薬組成物
WO2009092071A2 (en) 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof
DK2252312T3 (da) * 2008-02-07 2014-06-16 Univ Cornell Fremgangsmåder til forebyggelse eller behandling af insulinresistens
JP5909182B2 (ja) * 2009-08-12 2016-04-26 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
EP3338788A1 (en) * 2009-08-24 2018-06-27 Stealth Peptides International, Inc. Methods and copositions for preventing or treating opthalmic conditions
US20130040901A1 (en) * 2010-02-26 2013-02-14 University Of Florida Research Foundation Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3040080A1 (en) * 2010-03-15 2016-07-06 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
MX2013007168A (es) 2010-12-22 2013-11-04 Genentech Inc Anticuerpo anti-pcsk9 y metodos de uso.
JP2015529655A (ja) * 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法

Similar Documents

Publication Publication Date Title
JP2015529655A5 (cg-RX-API-DMAC7.html)
JP2015524439A5 (cg-RX-API-DMAC7.html)
Ito Dyslipidemia: management using optimal lipid-lowering therapy
AU2013296493B2 (en) Methods for treatment of atherosclerosis
Jones et al. Role of colesevelam in combination lipid-lowering therapy
JP2015503593A5 (cg-RX-API-DMAC7.html)
Marcus et al. Alternate-day dosing with statins
JP2018508551A5 (ja) 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物
Trentman et al. Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians
Backes et al. Optimal lipid modification: the rationale for combination therapy
Basile et al. Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy
Markel Statins and peripheral arterial disease
Pflieger et al. Medical management of stable coronary artery disease
Stein Management of dyslipidemia in the high-risk patient
JP2010505866A5 (cg-RX-API-DMAC7.html)
Woo et al. Comparison of the efficacy and safety of atorvastatin 40 mg/ω-3 fatty acids 4 g fixed-dose combination and atorvastatin 40 mg monotherapy in hypertriglyceridemic patients who poorly respond to atorvastatin 40 mg monotherapy: an 8-week, multicenter, randomized, double-blind Phase III Study
Lin et al. The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients
Ho et al. Statins and their interactions with other lipid-modifying medications: safety issues in the elderly
Katsiki et al. Exploring the management of statin intolerant patients: 2016 and beyond
JP6207560B2 (ja) 膵炎を治療するためのゲムカベンおよび誘導体
McGovern Niaspan®: creating a new concept for raising HDL-cholesterol
Davidson Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events
Moro et al. Non-antiarrhythmic drugs to prevent atrial fibrillation
Castaldo A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients
Korth et al. Hepatotoxic Effects of Lipid-altering Agents